Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 1
1(16.7%)
6Total
Phase 2(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05933525Phase 2Completed

Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

Role: lead

NCT03042767Phase 2Completed

Anti-LPS Antibody Treatment for Pediatric NAFLD

Role: collaborator

NCT02316717Phase 2Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Role: lead

NCT01968382Phase 2Completed

Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis

Role: collaborator

NCT03065374Phase 1Terminated

Treatment for Clostridium-difficile Infection With IMM529

Role: lead

NCT01466894Phase 2Withdrawn

Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Role: lead

All 6 trials loaded